Clinical Research Papers:
Possible benefits from post-mastectomy radiotherapy in node-negative breast cancer patients: a multicenter analysis in Korea (KROG 14-22)
Metrics: PDF 1446 views | HTML 2090 views | ?
Abstract
Hae Jin Park1, Kyung Hwan Shin2, Jin Ho Kim3, Seung Do Ahn4, Su Ssan Kim4, Yong Bae Kim5, Won Park6, Yeon-Joo Kim7, Hyun Soo Shin8, Jin Hee Kim9, Sun Young Lee10, Kyubo Kim11, Kyung Ran Park12 and Bae Kwon Jeong13
1 Departments of Radiation Oncology, Hanyang University Hospital, Seoul, Korea
2 Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea
3 Department of Radiation Oncology, Seoul National University Hospital, Seoul, Korea
4 Department of Radiation Oncology, University of Ulsan College of Medicine, Seoul, Korea
5 Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea
6 Department of Radiation Oncology, Sungkyunkwan University School of Medicine, Seoul, Korea
7 Department of Radiation Oncology, Proton Therapy Center, National Cancer Center, Goyang, Korea
8 Department of Radiation Oncology, CHA University School of Medicine, Pocheon, Korea
9 Department of Radiation Oncology, Keimyung University School of Medicine, Daegu, Korea
10 Department of Radiation Oncology, Chonbuk National University Hospital, Jeonju, Korea
11 Department of Radiation Oncology, Ewha Womans University School of Medicine, Seoul, Korea
12 Department of Radiation Oncology, Ewha Womans University Mokdong Hospital, Seoul, Korea
13 Department of Radiation Oncology, Gyeongsang National University School of Medicine, Jinju, Korea
Correspondence to:
Kyung Hwan Shin, email:
Keywords: breast cancer, post-mastectomy radiotherapy, risk factors
Received: January 02, 2017 Accepted: February 20, 2017 Published: March 15, 2017
Abstract
Purpose: This study was performed to identify a subset of patients who may benefit from post-mastectomy radiotherapy (PMRT) among node-negative breast cancer patients.
Materials and Methods: We retrospectively reviewed 1,828 patients with pT1-2N0 breast cancer, treated with mastectomy without PMRT from 2005 to 2010 at 10 institutions. Univariate and multivariate analyses for locoregional recurrence (LRR) and any first recurrence (AFR) were performed according to clinicopathologic factors and biologic subtypes.
Results: During a median follow-up period of 5.9 years (range: 0.7-10.4 years), 98 patients developed AFR (39 isolated LRR, 13 LRR with synchronous distant metastasis, and 46 isolated distant metastasis), and 52 patients developed LRR. The 7-year LRR and AFR rates were 3.8% and 6.7%, respectively. Multivariate analysis revealed that age of ≤ 40 years (p<0.001) and T2 stage (p=0.013) were independent risk factors for LRR. The 7-year LRR rates were 2.5% with no risk factors, 4.5% with one risk factor, and 12.4% with two risk factors. Multivariate analysis for AFR revealed that age of ≤ 40 years (p<0.001), T2 stage (p<0.001), and triple-negative biological subtype (p=0.045) were independent risk factors for AFR. The 7-year AFR rates were 3.9% with no risk factors, 8.4% with one risk factor, and 15.7% with two to three risk factors.
Conclusions: Mastectomy without PMRT is a sufficient local treatment for pT1-2N0M0 breast cancer. Nevertheless, PMRT might be considered for patients with two or three risk factors, among those of young age, with T2 tumors, and with the triple-negative biological subtype based on LRR and AFR.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16241